Integrin-linked kinase and its uses

Abstract

Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

What is claimed is:  
     
         1 . A method of inhibiting inflammation in a host, the method comprising: 
 contacting said host with an effective dose of an inhibitor of integrin linked kinase.    
     
     
         2 . The method according to  claim 1 , wherein said inhibitor is an anti-sense oligonucleotide that hybridizes with the nucleic acid sequence set forth in SEQ ID NO:1.  
     
     
         3 . The method according to  claim 1 , wherein said inhibitor comprises an ILK specific antibody.  
     
     
         4 . The method according to  claim 1 , wherein said inhibitor comprises a small organic molecule.  
     
     
         5 . The method according to  claim 4 , wherein said molecule blocks ILK catalytic activity.  
     
     
         6 . The method according to  claim 1 , wherein said inhibitor decreases the available level of [Ptdlns (3,4,5) P 3 ] in a cell.  
     
     
         7 . The method according to  claim 6 , wherein said inhibitor is wortmannin.  
     
     
         8 . The method according to  claim 6 , wherein said inhibitor is LY294002.  
     
     
         9 . The method of  claim 1 , wherein cellular migration is inhibited.  
     
     
         10 . A method of preventing inflammation in a host, the method comprising: 
 contacting said host with an effective dose of an inhibitor of integrin linked kinase.    
     
     
         11 . The method according to  claim 10 , wherein said inhibitor is an anti-sense oligonucleotide that hybridizes with the nucleic acid sequence set forth in SEQ ID NO:1.  
     
     
         12 . The method according to  claim 10 , wherein sai d inhibitor comprise s an ILK specific antibody.  
     
     
         13 . The method according to  claim 10 , wherein said inhibitor comprises a small organic molecule.  
     
     
         14 . The method according to  claim 13 , wherein said molecule blocks ILK catalytic activity.  
     
     
         15 . The method according to  claim 10 , wherein said inhibitor decreases the available level of [Ptdlns (3,4,5) P 3 ] in a cell.  
     
     
         16 . The method according to  claim 15 , wherein said inhibitor is wortmannin.  
     
     
         17 . The method according to  claim 15 , wherein said inhibitor is LY294002.  
     
     
         18 . The method of  claim 10 , wherein cellular migration is inhibited.